ANGLE
Pursuing a multi-faceted Parsortix commercial opportunityANGLE
FY22: a year of two very distinct halvesANGLE
Post-FDA approval commercial momentum is buildingANGLE
£20m raise funds commercialisation through to mid-2024ANGLE
Parsortix FDA clearance marks a key transition pointANGLE
FY21 results: prepared for commercial successANGLE
FDA approval awaited, LDT data expected H122ANGLE
Poised to disrupt existing tumour assay protocolsANGLE
First custom CTC assay development contractANGLE
£20m placing to accelerate Parsortix opportunities